The chemotherapy drugs 5-FU and capecitabine could harm or kill you if you have a variant in the DPYD gene. Request genetic testing before you take these drugs.

The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business a ...

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

This collaboration will enable Evexia Diagnostics'clinicians to access Genomind's advanced pharmacogenetic testing, empowering them to make more informed decisions and provide personalized care ...

1 On November 1, 2024, UnitedHealthcare ("UNH") updated its medical policy for commercial and individual exchange plans to ...

of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel pharmacogenetic tests, including Myriad’s GeneSight test, under its commercial and individual exchange ...

MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated medical policy from UnitedHealthcare restricting access to multi-gene panel ...